The effects of carcinogenic heterocyclic amines and -carbolines on 5-hydroxytryptamine-induced human platelet aggregation,-on the uptake of 5-hydroxytryptamine by platelets, and on human monoamine oxidase activity were investigated. Of the dietary carcinogens and -carbolines studied, carcinogenic tryptophan pyrolysis products had greater pharmacological activities than other heterocyclic amines. The carcinogenic tryptophan pyrolysis products, 3-amino-l,4-dimethyl-5H-pyrido [4,3-b]indole and 3-amino-l-methyl-5H-pyrido [4,3-b]indole, which have been identified in the dialysis fluid of uraemic patients, were the most potent inhibitors of the aggregation response to 5-hydroxytryptamine, with IC 50 (the concentrations causing 50% inhibition) values of 10 μιηοΐ/ΐ and 50 μιηοΐ/ΐ, respectively. 3-Amino-l,4-dimethyl-5H-pyrido[4,3-b]indoleand 3-amino-l-methyl-5H-pyrido [4,3-b]indole by themselves did not induce platelet aggregation, although these dietary carcinogens structurally resemble 54iydroxytryptamine. Kinetic analyses showed that 3-amino-l,4-dimethyl-5H-pyrido [4,3^b]indole and 3*amino-l-methyl-5H-pyrido [4,3-b]indole were potent competitive inhibitors of 5-hydroxytryptamine uptake by platelets with /ζ 18 μπιοΐ/ΐ and 42 μιηοΐ/ΐ, respectively. Furthermore, carcinogenic tryptophan pyrolysates as well as -carbolines were found to be competitive selective inhibitors of monoamine oxidase 'type A'.
Introduction
Among such carcinogens, 3-amino-l ,4-dimethyl-5H-During the last decade, a new series of heterocyclic pyrido [4,3-b] indole, 3-amino-l-methyl-5H-pyramines has been isolated as potent mutagens from ido [4,3-b] indole and γ-carboline derivatives, strongly pyrolysates of amino acids and proteins and from inhibit human platelet aggregation by inhibiting prosbroiled fish and meat (1, 2) . All the mutagenic het-taglandin endoperoxide synthetase (7) . In the course erocyclic amines so far tested have been shown to be of the previous study, we found that 3-amino-l,4-carcinogenic in experimental animals (1, 2) . Recently, dimethyl-5H-pyrido [4,3-b] indole and 3-amino-lsome mutagenic and carcinogenic heterocyclic amines methyl-5H-pyrido [4,3-b] indole are also potent inhibsuch as 3,amino-l,4-dimethyl-5H-pyrido [4,3-b] indole, itors of 5-hydroxytryptamine-induced human platelet 3-amino-l-methyl,5H-pyrido [4,3-b] indole, 2-amino-aggregation. Since aggregation induced by 5-hydroxyo-methyldipyridoIl^-arS'^'-dlimidazole and 2-ami-tryptamine is mediated by a specific receptor (8, 9) , nodipyrido[l>a:^2'-d]imidazote were identified in il is perhaps relevant that the tryptophan pyrolysis the dialysis fluid of patients with uraemia, and in products, 3-amino-l,4-dimethyl-5H-pyrido [4,3-b ]-human plasma (3) (4) (5) (6) .
indole and 3-amino-l -methyl-5H-pyrido [4,3-b] indole, are structurally related to 5-hydroxytryptamine (ser-0 Enzyme: Monoamine oxidase (amine: oxygen oxidoreduc-otonm). tese, deaminating, flavin-containing; E.G. 1.4.3.4) On the other hand
. car bo nes such as tetrahydro-*) This research was supported in part by a Grant-m-Aid for Λ , ,. , , ^ , , , A -· t -* Scientific Research firom the Ministry of Education, Science -carbohne have been reported to be selective mhiband Culture of Japan.
itors of monoamine oxidase A (EC 1.4.3.4) (10-12).
Furthermore, tetrahydro--carboline and/or its derivatives which structurally resemble 5-hydroxytryptamine were shown to be potent uptake inhibitors of 5-hydroxytryptamine in human platelets and mouse brain (11, 13) . These findings suggested us that 3-amino-1,4-dimethyl-5H-pyrido [4,3-b] indole and 3-amino-l-methyl-5H-pyrido [4,3-b] indole may be not only 5-hydroxytryptamine -uptake inhibitors but also potent monoamine oxidase inhibitors. In the present report, we describe the effects of carcinogenic tryptophan pyrolysates on 5-hydroxytryptamine-induced platelet aggregation, human platelet 5-hydroxytryptamine uptake and human monoamine oxidase activity in vitro. The chemical structures of the heterocyclic amines including -carbolines used in the present study are shown in figure 1. 
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Materials and Methods
Preparation of platelet-rich plasma
Human blood (9 vol) was collected in 1 vol of 38 g/1 trisodium citrate as an anticoagulant. The citrated blood was gently mixed and centrifuged at 180# for 20 min at 20 °C, and the supernatant (platelet-rich plasma) was carefully transferred with a plastic pipette into plastic tubes. For the preparation of plateletpoor plasma, the remainder of the blood was centrifuged at 3000 g for 15 min. For platelet aggregation studies, the platelet concentration of platelet-rich plasma was adjusted to 2-5 χ 10 n /l by addition of an appropriate amount of platelet-poor plasma (14) .
Platelet aggregation
This was performed at 37 °C using a Chronolog aggregometer (Chronolog Co., Havertown, PA, U.S.A.) (7, 14, 15) . Aggregation was measured as percent light transmission, using the light transmission of platelet-rich plasma as 0% and that of platelet-poor plasma as 100%. Platelet aggregation was initiated using 5-hydroxytryptamine and ADP. Added chemicals consisted of 10% of the final volume of the assay mixture (14) .
Hererocyclic amines were dissolved in saline and added to platelet-rich plasma just before the addition of the stimulator.
5-Hydroxytryptamine uptake studies
The uptake of [ 14 C]5-hydroxytryptamine into human platelets was determined by the method of Omen & Smith (16) with the following modification. Platelet-rich plasma was prepared from whole blood in sodium citrate instead of using EDTA, and platelet-rich plasma was diluted with saline instead of plateletpoor plasma, because the latter contains unknown inhibitors of 5-hydroxytryptamine uptake (17) . The average platelet counts in all experiments were in the range of 6-8 χ 10 n /l and the specific activity of the [ I4 C]5-hydroxytryptamine used was 7200-8400 Bq/pmol. Platelet-rich plasma was incubated at 37 °C in the small polypropylene centrifuge tubes with raT dioactive 5^hydroxytryptamine with or without the heterocyclic amines at different concentrations. The final volume in each tube was 1 ml. After incubation, the tubes were centrifuged in the Beckman Microfuge at 20 000 g for 30s. The supernatant was decanted and the inside of the tube above the platelet pellet was wiped with cotton-tipped applicators to remove final traces of plasma. The pellet was resuspended in 200 μΐ water and frozen and thawed twice to lyse the platelets and to release their 5-hydroxytryptamine (8) . The lysate was transferred into the vial of a scintillation counter. Each vial received 10 ml Scintisol EX-Η (Dojindo Laboratories, Kumamoto, Japan) and radioactivities were estimated by liquid scintillation counting. The radioactivity of the sample which was incubated at 0 °C was defined as the non-specific [ l4 C]5-hydroxytryptamine uptake. The specific uptake was calculated as total minus nonspecific uptake. Preliminary experiments showed in linear relationship between the incubation time (l min to 20 min) and the amount of incorporated radioactive 5-hydroxytryptamine. Therefore, in subsequent experiments, radioactive 5-hydroxytryptamine was incubated with platelet-rich plasma for 5 min.
Sources of monoamine oxidase
Human platelets were used as a source of monoamine oxidase B and human placenta as a source of monoamine oxidase A (18, 49) . Platelet-rich plasma (20 ml), prepared as described above, was centrifuged at 3000 g for 10 min. The supernatant was removed by decantation and the platelet pellets were washed with 0.32 mol/1 sucrose by suspension and resedirnentation at 3000 g. The pellets were finally resuspended in 2 ml of 0.32 mol/1 sucrose and finally sonicated with an ultrasonic disintegrator for 30 s and frozen at -20^0 for future use (20) . This volume contains a summary of the current advances in the field of pteridines and biogenic amines. Biochemical, analytical, immunological, and pediatric problems are the main themes discussed, but also interesting contributions from the fields of biogenic amines, chemistry, and medical applications of pteridines are presented. Each topic is introduced by a plenary lecture. Fresh human placenta (760 g) was washed three times with ice cold saline. An homogenate of placenta (100 g, made up with 10 mmol/1 phosphate b ffer, pH 7.4 to 1 liter) was prepared and frozen at -20 °C until use (12) . Before the monoamine oxidase assay, an aliquot was diluted twenty-fold with 100 mmol/1 phosphate buffer at pH 7.4. 14 C]phenylethylamine were diluted with non-radioactive substrate. Mixtures were incubated for 30 min at 37 °C and the reaction stopped on ice followed by the addition of 100 μΐ of 2mol/l citric acid (12) . The labelled products of the reaction were extracted into 3 ml of toluene/ ethylacetate (1 + 1, by vol) when 5-hydroxytryptamine was used as substrate, and into 3 ml of toluene for phenylethylamine (12) . Radioactivities were measured by liquid scintillation counting. All assays were carried out in duplicate and concentrations of heterocyclic amines causing 50% inhibition of [ 
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Results
Effects of heterocyclic amines on human platelet aggregation
It is well known that 5-hydroxytryptamine induces a transient reversible platelet aggregation in 90% of a normal population (8, 21) , while the platelet aggregation response to ADP is biphasic and irreversible at high doses of the stimulant. Aggregation induced by these stimulants is mediated by specific receptors, The Km value of the platelet aggregation response to 5-hydroxytryptamine was determined from the initial rate of aggregation induced by concentrations of 5-hydroxytryptamine ranging from 1.0 -20 μηιοΐ/ΐ (11). Although these heterocyclic amines structurally resemble 5-hydroxytryptamine ( fig. 1 ), none of them was capable of inducing platelet aggregation, even at a high concentration as 100 μηιοΐ/ΐ. In addition, we reconfirmed that these heterocyclic amines did not affect the first wave ADP-induced aggregation, as reported previously (7).
Effects of heterocyclic amines on 5-hydroxytryptamine uptake by human platelets
We also examined the effect of heterocyclic amines on 5-hydroxytryptamine uptake by platelets, not only because the carcinogenic heterocyclic amines structurally resemble 5-hydroxytryptamine ( fig. 1 ), but also because some of the heterocyclic amines examined in this study had potent inhibitory effects on the platelet aggregation response to 5-hydroxytryptamine. In the present system, the K m for 5-hydroxytryptamine uptake was 1.6-2.2 μιηοΐ/ΐ (1.8 ± 0.25 μιηοΐ/ΐ, mean ± S. D., n = 4) with a F max of 16.5 pmol/5 min per 10 7 platelets. These results are slightly higher than those reported previously (11, 16) . This may be due to differences in the anticoagulant used, the extraction procedure for radioactive 5-hydroxytryptamine, or the dilution medium used for the platelet-rich plasma.
It was confirmed by kinetic analysis that the inhibition by 3-amino-l,4-dimethyl-5H-pyrido [4,3-b] indole is competitive with 5-hydroxytryptamine, with a K { value of 18 μιηοΐ/ΐ. Other heterocyclic amines such as 3-amino-l-methyl-5H-pyrido [4,3-b] indole, tetrahydro--carboline and harmine were less potent inhibitors than 3-amino-l ,4-dimethyl-5H-pyrido[4,3-b]-indole. The K { values are summarized in table 2; 3-amino-l,4-dimethyl-5H-pyrido [4,3-b] indole is the most potent inhibitor among the heterocyclic amines studied.
Tab. 2. Effects of heterocyelic amines on platelet 5-hydroxytryptamine uptake. 
Effects of heterocyclic amines on monoamine oxidase
Monoamine oxidase is now classified into two types, monoamine oxidase-A and -B, according to their sensitivity to the specific inhibitors and their substrate specificities. -Carbolines such as harmine and harman as well as other structural analogues of the barman series are known to be reversible and competitive inhibitors of monoamine oxidase-A (10 -13). Human platelets have been shown to contain almost exclusively the B type, whereas human placenta contains only the A type (18, 19) . Therefore, human placenta was used as a source of pure monoamine oxidase-A and human platelets as a source of monoamine oxidase-B. Using the monoamine oxidase-Aselective substrate, 5-hydroxytryptamine, and the monoamine oxidase-B-selective substrate, phenylethylamine, the IC 50 values were determined for the inhibition of monoamine oxidase-A and -B. Figure 3 shows the inhibition by heterocyclic amines of the monoamine oxidase-A activity of human placenta homogenate towards 10.4 μιηοΐ/ΐ 5-hydroxytryptamine. The curves obtained with the heterocyclic amines indicate the 3-amino-l,4-dimethyl-5H-pyrido [4,3-b] indole and 3-amino-l-methyl^SH-pyrido [4,3-b] indole, tryptophan pyrolysis products, were more potent monoamine oxidase-A inhibitors than other carcinogenic heterocyclic ahiines including 2- 
Tab. 3. Effects of heterocyclic amines on human placenta and platelet monoamine oxidase (MAO) activities.
Heterocyclic Amines ICso* (μηιοΐ/ΐ) Carcinogenic heterocyclic amines fig. 1 ). In this investigation, however, 3-amino-l ,4-dimethyl-5H-pyrido [4,3-b] indole and 3-amino-l -methyl-5H-pyrido [4,3-b] indole had more potent inhibitory effects on 5-hydroxytryptamine-induced platelet aggregation and platelet 5-hydroxytryptamine uptake than -carbolines, which structurally resemble 5-hydroxytryptamine ( fig. 1, tab. 1 and 2) . The reason was not clear, but an amino-group of 3-amino-l ,4-dimethyl-5H-pyrido [4,3-b] indole and 3-amino-l -methyl-5H-pyrido [4,3-b] indole might play an important role in their inhibitory actions on the platelet response to 5-hydroxytryptamine ( fig. 1 ). On the other hand, -carbolines such as tetrahydro--carboline, harman and harmine as well as other structural analogues of harman series are known to be reversible and competitive inhibitors of monoamine oxidase-A (10 -13) . In this study, we reconfirmed that -carbolines were selective monoamine oxidase-A inhibitors. Moreover, we found that 3-amino-l,4-dimethyl-5H-pyrido [4,3-b] indole, 3-amino-l-methyl-5H-pyrido [4,3-b] indole, and γ-carbolines were also potent inhibitors of monoamine oxidase-A ( fig. 3 and tab. 3) . The results Manabe el ah: -Carbolines and monoamine metabolism showed that 3-amino-l ,4-dimethyl-5H-pyrido- [4,3-b] indole and 3-amino-l -methyl-5H-pyrido [4,3-b] indole were more potent inhibitors of monoamine oxidase-A than ß-carbolines, with the exception of harmine. However, we could not provide a satisfactory explanation for the observation that harmine was the most potent inhibitor of monoamine oxidase-A in the heterocyclic amines studied (tab. 3). (3) (4) (5) (6) . The mean absolute amounts of 3-amino-l,4-dimethyl-5H-pyrido [4,3-b] indole and 3-amino-l-methyl-5H-pyrido [4,3-b] indole in the dialysis fluid (6 -liters) were 727 pmol and 206 pmol, respectively (4) . The concentrations of the carcinogenic heterocyclic amines in human plasma seem to be well below those causing significant effects on the platelet response to 5-hydroxytryptamine or on monoamine oxidase activities. However, as mentioned in our previous report (7), many factors, such as the in vivo tissue distribution and accumulation of 3-amino-1,4-dimethyl-5H-pyfido [4,3-b] indole and 3-amino-l-methyl-5H-pyrido [4,3-b] itfdole, remain to be investigated before the potential of tryptophan pyrolysis products for affecting cells such as platelets in vivo can be determined.
In conclusion, 3-amino-l ,4-dimethyl-5H-pyrido [4,3-b] indole and 3-amino-l -methyl-5H-pyrido [4,3-b] indole, carcinogenic tryptophan pyrolysates, are potent inhibitors of the platelet aggregation response to 5-hydroxytryptamine, 5-hydroxytryptamine uptake by platelets and monoamine oxidase-A activity.
